Vymada 50 mg Tablet

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Vymada 50 mg Tablet is a combination of two medicines, sacubitril and valsartan. Its labelling describes it as lowering the chances of hospital admission and preventing deaths in people with chronic heart failure, helping the heart work better and improving overall health. In heart failure the heart cannot pump enough blood to the lungs and other organs, causing breathlessness, tiredness, and swelling. The combination is described as lowering blood pressure so it becomes easier for the heart to pump blood effectively, improving heart function and relieving symptoms.

Active ingredients
Sacubitril and valsartan
Strength
50 mg
Dosage form
Oral tablet
Therapeutic class
Angiotensin receptor-neprilysin inhibitor (ARNI)
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Described for the treatment of heart failure
  • Described as lowering the chances of hospital admission and preventing deaths in people with chronic heart failure
  • Described as lowering blood pressure so the heart can pump blood more effectively, improving heart function and relieving symptoms
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Taken only after consulting a doctor
  • Taken as per the dosage advised by the doctor
  • Not to be taken without consulting the doctor

Described Side Effects

Commonly described side effects include:

  • Hypotension (low blood pressure)
  • Cough
  • Dizziness
  • High potassium level in the blood
  • Renal (kidney) issues

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Not to be taken without consulting the doctor
  • The doctor should be informed of any kidney or liver-related problems
  • Described as to be avoided if pregnant or breastfeeding
  • A proper diet should be followed so the body can function properly

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical and healthcare products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling it is a combination of sacubitril and valsartan used for the treatment of chronic heart failure. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.

Its labelling describes the combination as lowering blood pressure so it becomes easier for the heart to pump blood effectively, improving heart function and relieving symptoms of heart failure.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services